PubRank

A Sette

Author PubWeight™ 342.26‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000 9.80
2 The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science 1987 5.32
3 Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med 1999 4.93
4 Isolation and characterization of antigen-Ia complexes involved in T cell recognition. Cell 1986 4.71
5 Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994 4.42
6 Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995 4.31
7 The minimal number of class II MHC-antigen complexes needed for T cell activation. Science 1990 4.09
8 Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998 3.95
9 Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993 3.80
10 Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J Immunol 1998 3.65
11 Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature 1987 3.63
12 The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001 3.52
13 Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 1996 3.45
14 Differential effects of cytolytic T cell subsets on intracellular infection. Science 1997 3.39
15 Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science 1992 3.39
16 Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J Exp Med 1998 3.35
17 The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995 3.34
18 Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 1992 3.24
19 Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 1997 2.99
20 Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994 2.90
21 Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med 1995 2.80
22 Immunological self, nonself discrimination. Science 1987 2.59
23 Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol 1997 2.57
24 Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med 1994 2.37
25 Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 1995 2.34
26 CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing. J Virol 2001 2.34
27 Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. Virology 1998 2.31
28 Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 2000 2.29
29 The interaction between protein-derived immunogenic peptides and Ia. Immunol Rev 1987 2.24
30 Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. J Immunol 1996 2.24
31 Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med 1994 2.18
32 Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 1996 2.17
33 Conserved T cell receptor repertoire in primary and memory CD8 T cell responses to an acute viral infection. J Exp Med 1998 2.13
34 Definition of specific peptide motifs for four major HLA-A alleles. J Immunol 1994 2.11
35 Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways. Nature 1990 2.11
36 Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med 2001 2.10
37 Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994 2.07
38 Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 1995 2.05
39 Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol 1997 1.98
40 Autologous peptides constitutively occupy the antigen binding site on Ia. Science 1988 1.92
41 Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity 1997 1.84
42 Human memory CTL response specific for influenza A virus is broad and multispecific. Hum Immunol 2000 1.84
43 Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 1995 1.83
44 HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J Immunol 2000 1.82
45 Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today 1996 1.79
46 A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 1999 1.75
47 Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest 1993 1.73
48 Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J Clin Invest 2001 1.72
49 Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 1998 1.72
50 MHC interaction and T cell recognition of carbohydrates and glycopeptides. J Immunol 1992 1.71
51 Immunogenic and encephalitogenic epitope clusters of myelin proteolipid protein. J Immunol 1996 1.70
52 Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. Hum Immunol 2001 1.68
53 Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995 1.67
54 Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. J Virol 2001 1.65
55 Antimicrobial activity of MHC class I-restricted CD8+ T cells in human tuberculosis. Proc Natl Acad Sci U S A 2000 1.65
56 Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes. J Virol 2001 1.62
57 Immunodominance analysis of CTL responses to influenza PR8 virus reveals two new dominant and subdominant Kb-restricted epitopes. J Immunol 1996 1.61
58 Measurement of MHC/peptide interactions by gel filtration. Curr Protoc Immunol 2001 1.60
59 Structure-based prediction of binding peptides to MHC class I molecules: application to a broad range of MHC alleles. Protein Sci 2000 1.58
60 Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med 2001 1.57
61 The peptide-binding motif for the human transporter associated with antigen processing. J Exp Med 1995 1.56
62 Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci U S A 1994 1.56
63 The curation guidelines of the immune epitope database and analysis resource. Cytometry A 2008 1.56
64 Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum Immunol 1996 1.52
65 Interaction of an immunodominant epitope with Ia molecules in T-cell activation. Proc Natl Acad Sci U S A 1988 1.51
66 Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. J Clin Invest 1997 1.50
67 Major histocompatibility complex binding affinity of an antigenic determinant is crucial for the differential secretion of interleukin 4/5 or interferon gamma by T cells. Proc Natl Acad Sci U S A 1995 1.49
68 HLA-DR53 molecules are associated with susceptibility to celiac disease and selectively bind gliadin-derived peptides. Immunogenetics 1999 1.49
69 Characterization of a naturally processed MHC class II-restricted T-cell determinant of hen egg lysozyme. Nature 1989 1.46
70 Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J Immunol 1999 1.46
71 Isoaspartyl post-translational modification triggers autoimmune responses to self-proteins. J Biol Chem 1999 1.45
72 T cell determinants from autoantibodies to DNA can upregulate autoimmunity in murine systemic lupus erythematosus. J Exp Med 1995 1.44
73 Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol 1997 1.43
74 Characterization of the specificity of peptide binding to four DR haplotypes. J Immunol 1990 1.43
75 Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J Immunol 1999 1.41
76 Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development. Hepatology 1999 1.39
77 Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. J Immunol 1999 1.39
78 Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 2001 1.38
79 A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J Immunol 1994 1.38
80 Definition of five new simian immunodeficiency virus cytotoxic T-lymphocyte epitopes and their restricting major histocompatibility complex class I molecules: evidence for an influence on disease progression. J Virol 2000 1.37
81 Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J Immunol 1995 1.35
82 A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens. Proc Natl Acad Sci U S A 1997 1.33
83 Uncovering subdominant cytotoxic T-lymphocyte responses in lymphocytic choriomeningitis virus-infected BALB/c mice. J Virol 1997 1.32
84 Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: implications for vaccine development. J Immunol 1997 1.32
85 The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 1998 1.31
86 Meta-analysis of immune epitope data for all Plasmodia: overview and applications for malarial immunobiology and vaccine-related issues. Parasite Immunol 2009 1.30
87 Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J Immunol 2000 1.28
88 Pocket 4 of the HLA-DR(alpha,beta 1*0401) molecule is a major determinant of T cells recognition of peptide. J Exp Med 1995 1.28
89 Conserved MHC class I peptide binding motif between humans and rhesus macaques. J Immunol 2000 1.26
90 Truncation analysis of several DR binding epitopes. J Immunol 1991 1.24
91 In vivo selection of a lymphocytic choriomeningitis virus variant that affects recognition of the GP33-43 epitope by H-2Db but not H-2Kb. J Virol 2001 1.23
92 Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum. Pharm Res 1993 1.23
93 Specificity and degeneracy in peptide binding to HLA-B7-like class I molecules. J Immunol 1996 1.21
94 Effect of T-cell receptor antagonism on interaction between T cells and antigen-presenting cells and on T-cell signaling events. Proc Natl Acad Sci U S A 1993 1.21
95 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination. J Immunol 2000 1.21
96 Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur J Immunol 1996 1.21
97 DRB1*0301 molecules recognize a structural motif distinct from the one recognized by most DR beta 1 alleles. J Immunol 1992 1.20
98 Relative contribution of "determinant selection" and "holes in the T-cell repertoire" to T-cell responses. Proc Natl Acad Sci U S A 1989 1.20
99 Naturally processed peptides longer than nine amino acid residues bind to the class I MHC molecule HLA-A2.1 with high affinity and in different conformations. J Immunol 1994 1.19
100 Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A 2000 1.19
101 Utilization of genomic sequence information to develop malaria vaccines. J Exp Biol 2003 1.19
102 Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J Immunol 2001 1.18
103 Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res 1996 1.18
104 Definition of the Mamu A*01 peptide binding specificity: application to the identification of wild-type and optimized ligands from simian immunodeficiency virus regulatory proteins. J Immunol 2000 1.17
105 Altered ligands reveal limited plasticity in the T cell response to a pathogenic epitope. J Exp Med 1999 1.17
106 Recognition of multiple peptide cores by a single T cell receptor. J Exp Med 1995 1.17
107 Identification of A2-restricted hepatitis C virus-specific cytotoxic T lymphocyte epitopes from conserved regions of the viral genome. Int Immunol 1996 1.16
108 T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis. Eur J Immunol 1994 1.16
109 Negative selection of CD4+ CD8+ thymocytes by T-cell receptor peptide antagonists. Proc Natl Acad Sci U S A 1994 1.15
110 Determinants of T cell reactivity to the Mycobacterium leprae GroES homologue. J Immunol 1997 1.14
111 HLA-DR3 molecules can bind peptides carrying two alternative specific submotifs. J Immunol 1994 1.14
112 Peptide stability in drug development: a comparison of peptide reactivity in different biological media. J Pharm Sci 1992 1.14
113 The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunol Res 1998 1.12
114 Degenerate immunogenicity of an HLA-A2-restricted hepatitis B virus nucleocapsid cytotoxic T-lymphocyte epitope that is also presented by HLA-B51. J Virol 2001 1.12
115 Virus-specific CD8(+) T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection. Eur J Immunol 2001 1.12
116 T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease patients. Infect Immun 2001 1.11
117 Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J Immunol 1999 1.11
118 Free ligand-induced dissociation of MHC-antigen complexes. J Immunol 1991 1.10
119 High affinity for class II molecules as a necessary but not sufficient characteristic of encephalitogenic determinants. Int Immunol 1992 1.10
120 Human class I supertypes and CTL repertoires extend to chimpanzees. J Immunol 1998 1.10
121 Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 1999 1.10
122 Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 2000 1.09
123 Inhibition of experimental autoimmune encephalomyelitis induction in SJL/J mice by using a peptide with high affinity for IAs molecules. J Immunol 1990 1.09
124 Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996 1.08
125 HLA-A2-restricted cytotoxic T lymphocyte responses to multiple Plasmodium falciparum sporozoite surface protein 2 epitopes in sporozoite-immunized volunteers. J Immunol 1995 1.08
126 T cell receptor antagonism mediated by interaction between T cell receptor junctional residues and peptide antigen analogues. J Immunol 1993 1.08
127 A computational resource for the prediction of peptide binding to Indian rhesus macaque MHC class I molecules. Vaccine 2005 1.08
128 T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans. J Immunol 1995 1.07
129 Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules. J Immunol 1995 1.06
130 Differential T cell signaling induced by antagonist peptide-MHC complexes and the associated phenotypic responses. J Immunol 1997 1.06
131 Derivation of HLA-A11/Kb transgenic mice: functional CTL repertoire and recognition of human A11-restricted CTL epitopes. J Immunol 1997 1.06
132 Vaccination to treat persistent viral infection. Virology 2000 1.05
133 HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J Immunol 1998 1.05
134 Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine 1997 1.05
135 Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am J Obstet Gynecol 1996 1.05
136 Recognition by class II alloreactive T cells of processed determinants from human serum proteins. Science 1991 1.05
137 Strong similarities in antigen fine specificity among DRB1* 1302-restricted tetanus toxin tt830-843-specific TCRs in spite of highly heterogeneous CDR3. J Immunol 1995 1.04
138 The simian immunodeficiency virus envelope glycoprotein contains two epitopes presented by the Mamu-A*01 class I molecule. J Virol 1999 1.04
139 A disease-related epitope of Torpedo acetylcholine receptor. Residues involved in I-Ab binding, self-nonself discrimination, and TCR antagonism. J Immunol 1994 1.04
140 Molecular features of the hepatitis B virus nucleocapsid T-cell epitope 18-27: interaction with HLA and T-cell receptor. Hepatology 1997 1.04
141 The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J Immunol 1997 1.03
142 Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 1998 1.03
143 gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells. Br J Cancer 2001 1.02
144 The use of peptide analogs with improved stability and MHC binding capacity to inhibit antigen presentation in vitro and in vivo. J Immunol 1990 1.02
145 Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells. Int J Cancer 1998 1.02
146 Definition of a DQ3.1-specific binding motif. J Immunol 1994 1.01
147 Human infection with Trypanosoma cruzi induces parasite antigen-specific cytotoxic T lymphocyte responses. J Clin Invest 1998 1.01
148 Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. Int J Cancer 1999 1.00
149 A microcomputer program for probit analysis of interleukin-2 (IL-2) titration data. J Immunol Methods 1986 1.00
150 Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for therapeutic potential of MHC-blocking peptides. J Immunol 1994 0.99
151 Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J Immunol 1998 0.99
152 Molecular determinants of peptide binding to two common rhesus macaque major histocompatibility complex class II molecules. J Virol 2001 0.98
153 Tolerance to a self-peptide from the third hypervariable region of HLA DRB1*0401 in rheumatoid arthritis patients and normal subjects. J Immunol 1994 0.98
154 Spreading of HIV-specific CD8+ T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity. Hum Immunol 2001 0.98
155 Comparison of structural requirements for interaction of the same peptide with I-Ek and I-Ed molecules in the activation of MHC class II-restricted T cells. J Immunol 1991 0.98
156 Definition of an optimal cytotoxic T lymphocyte epitope in the latently expressed Kaposi's sarcoma-associated herpesvirus kaposin protein. J Infect Dis 2001 0.98
157 Complementary mutations in an antigenic peptide allow for crossreactivity of autoreactive T-cell clones. Proc Natl Acad Sci U S A 1996 0.98
158 Termination of peripheral tolerance to a T cell epitope by heteroclitic antigen analogues. J Immunol 1998 0.97
159 Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses. Clin Exp Immunol 2012 0.97
160 Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res 1999 0.97
161 Peptide analogs with different affinites for MHC alter the cytokine profile of T helper cells. Int Immunol 1996 0.97
162 Autoantigen recognition by human CD8 T cell clones: enhanced agonist response induced by altered peptide ligands. J Immunol 1997 0.96
163 Comparison of cytotoxic T lymphocyte responses induced by peptide or DNA immunization: implications on immunogenicity and immunodominance. Eur J Immunol 1997 0.96
164 A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets. Hum Immunol 1997 0.96
165 Altered Th1/Th2 balance associated with the immunosuppressive/protective effect of the H-2Ab allele on the response to allo-4-hydroxyphenylpyruvate dioxygenase. Eur J Immunol 1995 0.96
166 Expansion by self antigen is necessary for the induction of experimental autoimmune encephalomyelitis by T cells primed with a cross-reactive environmental antigen. J Immunol 1998 0.95
167 Immunization with the HBV core 18-27 epitope elicits CTL responses in humans expressing different HLA-A2 supertype molecules. Hum Immunol 1999 0.95
168 Self peptide requirement for class II major histocompatibility complex allorecognition. Proc Natl Acad Sci U S A 1991 0.94
169 Promiscuous presentation and recognition of nucleosomal autoepitopes in lupus: role of autoimmune T cell receptor alpha chain. J Exp Med 1998 0.93
170 Viral mutations, TCR antagonism and escape from the immune response. Curr Opin Immunol 1995 0.93
171 Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 1998 0.93
172 Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res 1997 0.93
173 The inhibition of different T cell lines specific for the same antigen with TCR antagonist peptides. J Immunol 1993 0.92
174 Differential activation of proliferation and cytotoxicity in human T-cell lymphotropic virus type I Tax-specific CD8 T cells by an altered peptide ligand. Proc Natl Acad Sci U S A 1995 0.91
175 In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells. Crit Rev Immunol 1998 0.91
176 Peripheral T cell response to A-gliadin in celiac disease: differential processing and presentation capacities of Epstein-Barr-transformed B cells and fibroblasts. Clin Immunol Immunopathol 1994 0.89
177 Autoreactive cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected subjects. J Exp Med 1996 0.88
178 Pan DR binding sequence provides T-cell help for induction of protective antibodies against Plasmodium yoelii sporozoites. Vaccine 1999 0.88
179 Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995 0.88
180 Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. Clin Cancer Res 2001 0.88
181 Identification of paramyosin T cell epitopes associated with human resistance to Schistosoma mansoni reinfection. Clin Exp Immunol 2005 0.87
182 Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles. Mol Immunol 1994 0.87
183 The HLA-A*0207 peptide binding repertoire is limited to a subset of the A*0201 repertoire. Hum Immunol 1997 0.86
184 Constitutive presentation of dominant epitopes from endogenous naturally processed self-beta 2-microglobulin to class II-restricted T cells leads to self-tolerance. J Immunol 1995 0.86
185 Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. Cancer Res 1997 0.86
186 Characterization of an in situ IFN-gamma ELISA assay which is able to detect specific peptide responses from freshly isolated splenocytes induced by DNA minigene immunization. J Immunol Methods 2000 0.86
187 Two distinct HLA-A*0101-specific submotifs illustrate alternative peptide binding modes. Immunogenetics 1997 0.86
188 Selective immunosuppression by administration of major histocompatibility complex (MHC) class II-binding peptides. I. Evidence for in vivo MHC blockade preventing T cell activation. J Exp Med 1992 0.86
189 Epitope selection and development of peptide based vaccines to treat cancer. Semin Cancer Biol 1995 0.85
190 Recognition of a novel naturally processed, A2 restricted, HCV-NS4 epitope triggers IFN-gamma release in absence of detectable cytopathicity. Hum Immunol 1998 0.85
191 Microbial epitopes act as altered peptide ligands to prevent experimental autoimmune encephalomyelitis. J Exp Med 1999 0.85
192 Lipopeptide particles as the immunologically active component of CTL inducing vaccines. Vaccine 1999 0.85
193 Heteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: implications for autoimmunity. Proc Natl Acad Sci U S A 1998 0.85
194 In vitro induction of primary, antigen-specific CTL from human peripheral blood mononuclear cells stimulated with synthetic peptides. Mol Immunol 1995 0.84
195 Peptide vaccines against hepatitis B virus: from animal model to human studies. Mol Immunol 2001 0.84
196 Biologic significance and therapeutic implications of antigen/MHC interactions. Clin Immunol Immunopathol 1989 0.83
197 Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization. AIDS Res Hum Retroviruses 1998 0.83
198 A subdominant CD8(+) cytotoxic T lymphocyte (CTL) epitope from the Plasmodium yoelii circumsporozoite protein induces CTLs that eliminate infected hepatocytes from culture. Infect Immun 2000 0.83
199 Identification of five different Patr class I molecules that bind HLA supertype peptides and definition of their peptide binding motifs. J Immunol 2000 0.83
200 Tools of the trade in vaccine design. Science 2000 0.82
201 Tolerance to a self peptide from the third hypervariable region of the Es beta chain. Implications for molecular mimicry models of autoimmune disease. Eur J Immunol 1991 0.81
202 DR alpha: E beta heterodimers in DRA transgenic mice hinder expression of E alpha: E beta molecules and are more efficient in antigen presentation. Int Immunol 1995 0.81
203 Gorillas with spondyloarthropathies express an MHC class I molecule with only limited sequence similarity to HLA-B27 that binds peptides with arginine at P2. J Immunol 2001 0.81
204 Analysis of lysozyme-specific immune responses by synthetic peptides. I. Characterization of antibody and T cell-mediated responses to the N-terminal peptide of hen egg-white lysozyme. Eur J Immunol 1986 0.81
205 T cell recognition of flanking residues of murine invariant chain-derived CLIP peptide bound to MHC class II. Cell Immunol 1998 0.81
206 Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses. Vaccine 1998 0.81
207 Synthetic antigenic peptides as a new strategy for immunotherapy of cancer. Biomed Pept Proteins Nucleic Acids 1995 0.81
208 Identification of an HSV-1/HSV-2 cross-reactive T cell determinant. J Immunol 1990 0.80
209 Facts on the fragmentation of antigens in presenting cells, on the association of antigen fragments with MHC molecules in cell-free systems, and speculation on the cell biology of antigen processing. Immunol Rev 1988 0.80
210 Antigen recognition. Curr Opin Immunol 2000 0.80
211 Binding and internalization of the 163-171 fragment of human IL-1 beta. Cytokine 1992 0.80
212 Non-malignant consequences of decreasing asbestos exposure in the Brazil chrysotile mines and mills. Occup Environ Med 2005 0.80
213 Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis. J Immunol Methods 2000 0.80
214 Rationally engineered proteins or antibodies with absent or reduced immunogenicity. Curr Med Chem 2002 0.80
215 Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2 / neu: possible immunotherapy for colorectal carcinomas. Br J Cancer 2001 0.80
216 Customized versus universal scoring functions: application to class I MHC-peptide binding free energy predictions. Bioorg Med Chem Lett 2001 0.79
217 Major histocompatibility complex class II association and induction of T cell responses by carbohydrates and glycopeptides. Springer Semin Immunopathol 1993 0.79
218 How T cells see antigen. Sci Am 1989 0.79
219 Intravenous or intranasal administration of gliadin is able to down-regulate the specific immune response in mice. Scand J Immunol 1999 0.79
220 Relation of HLA class I and II supertypes with spontaneous clearance of hepatitis C virus. Genes Immun 2013 0.79
221 MHC blocking peptides and T-cell receptor antagonists: novel paths to selective immunosuppression? Chem Immunol 1995 0.79
222 The self-directed T cell repertoire against mouse lysozyme reflects the influence of the hierarchy of its own determinants and can be engaged by a foreign lysozyme. J Immunol 1999 0.79
223 Class I MHC-peptide interactions: structural requirements and functional implications. Cancer Surv 1995 0.79
224 Peptide vaccination using nonionic block copolymers induces protective anti-viral CTL responses. Vaccine 1999 0.78
225 Inhibition of antigen presentation in vitro and in vivo by MHC antagonist peptides. Int Rev Immunol 1990 0.78
226 A DR17-restricted T cell epitope from a secreted Mycobacterium tuberculosis antigen only binds to DR17 molecules at neutral pH. Eur J Immunol 1997 0.78
227 Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes. Clin Cancer Res 1999 0.78
228 Design and testing of peptide-based cytotoxic T-cell-mediated immunotherapeutics to treat infectious diseases and cancer. Pharm Biotechnol 1995 0.78
229 TCR antagonism and T cell tolerance can be independently induced in a DR-restricted, hemagglutinin-specific T cell clone. Int Immunol 1994 0.77
230 Mutating the anchor residues associated with MHC binding inhibits and deviates CD8+ T cell mediated protective immunity against malaria. Mol Immunol 2006 0.77
231 HLA-A*01-restricted cytotoxic T-lymphocyte epitope from the Plasmodium falciparum circumsporozoite protein. Infect Immun 2001 0.77
232 Structural requirements and biological significance of interactions between peptides and the major histocompatibility complex. Philos Trans R Soc Lond B Biol Sci 1989 0.77
233 Supermotif peptide binding and degeneracy of MHC: peptide recognition in an EBV peptide-specific CTL response with highly restricted TCR usage. Hum Immunol 2000 0.76
234 Immunogenicity of self antigens is unrelated to MHC-binding affinity: T-cell determinant structure of Golli-MBP in the BALB/c mouse. J Autoimmun 2000 0.76
235 Antigen analogues as antagonists of the T cell receptor. Clin Exp Rheumatol 1993 0.76
236 Tools of the trade in vaccine design. Science 2000 0.76
237 CD4+ T cells from HIV-1-infected patients recognize wild-type and mutant human immunodeficiency virus-1 protease epitopes. Clin Exp Immunol 2011 0.75
238 A microcomputer program for hydrophilicity and amphipathicity analysis of protein antigens. Mol Immunol 1986 0.75
239 Class I MHC-peptide interaction: structural and functional aspects. Behring Inst Mitt 1994 0.75
240 Structural characteristics of peptides required for their interaction with IAd. Ann N Y Acad Sci 1988 0.75
241 Fine restriction analysis and inhibition of antigen recognition in HLA-DQ-restricted T cells by major histocompatibility complex blockers and T cell receptor antagonists. Eur J Immunol 1993 0.75
242 Studies on the nature of physiologically processed antigen and on the conformation of peptides required for interaction with MHC. Cold Spring Harb Symp Quant Biol 1989 0.75
243 Expression of T-cell receptor by a mouse monoclonal antigen-specific suppressor T-cell line. Curr Top Microbiol Immunol 1986 0.75
244 Analysis of MHC-specific peptide motifs. Applications in immunotherapy. Adv Exp Med Biol 1995 0.75
245 ["The memory effect" in healthy heart and transplanted heart. "Cor se ipse alit, se ipse movet, se ipse reget"]. Recenti Prog Med 2000 0.75
246 Dendritic cells generated in vivo by a chimeric hematopoietic growth factor, progenipoietin-4, demonstrate potent immunological function. Vaccine 2001 0.75
247 Synthetic peptides in the analysis of T cell interactions. Ann Sclavo Collana Monogr 1984 0.75
248 Synthetic peptides in the analysis of the induction and regulation of delayed-type hypersensitivity to lysozyme. Folia Biol (Praha) 1985 0.75
249 The influence of MHC class II molecules containing the rheumatoid arthritis shared epitope on the immune response to aggrecan G1 and its peptides. Scand J Immunol 2007 0.75
250 Differential signaling and hierarchical response thresholds induced by an immunodominant peptide of myelin basic protein and an altered peptide ligand in human T cells. Hum Immunol 1998 0.75
251 Response of CFU-GM to increasing doses of rhGM-CSF in patients with aplastic anemia. Exp Hematol 1991 0.75
252 The multivalent minigene approach to vaccine development. Expert Opin Investig Drugs 1999 0.75
253 Antigen analogs as therapeutic agents. Adv Exp Med Biol 1995 0.75